{
  "pmcid": "5058646",
  "sha256": "83a6127223e074b29470efd0beaf20520a4b2bc77b09fd9c5b116c814565ef4e",
  "timestamp_utc": "2025-11-09T16:02:12.935235+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.947281676898402,
    "reading_ease": 35.73388750622203,
    "word_count": 441
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "METHODS:: A pragmatic randomized, controlled, pivotal trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Subjects had Visual Analog Scale scores of ≥5.0/10.0 cm for both back and leg pain, and were assigned randomly (1:1)"
      },
      "Participants": {
        "score": 2,
        "evidence": "Subjects had Visual Analog Scale scores of ≥5.0/10.0 cm for both back and leg pain, and were assigned randomly (1:1) to receive HF10 therapy or low-frequency SCS."
      },
      "Intervention": {
        "score": 2,
        "evidence": "assigned randomly (1:1) to receive HF10 therapy or low-frequency SCS."
      },
      "Objective": {
        "score": 1,
        "evidence": "OBJECTIVE:: To compare long-term results of HF10 therapy and traditional low-frequency SCS."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary end point was a responder rate, defined as ≥50% back pain reduction from baseline at 3 months"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Subjects had Visual Analog Scale scores of ≥5.0/10.0 cm for both back and leg pain, and were assigned randomly (1:1)"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "In the study, 198 subjects were randomized (101 HF10 therapy, 97 traditional SCS)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "One hundred seventy-one subjects (90 HF10 therapy, 81 traditional SCS) successfully completed a short-term trial and were implanted."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "At 24 months, more subjects were responders to HF10 therapy than traditional SCS (back pain: 76.5% vs 49.3%; 27.2% difference, 95% CI, 10.1%-41.8%; P < .001 for non-inferiority and superiority; leg pain: 72.9% vs 49.3%; 23.6% difference, 95% CI, 5.9%-38.6%; P < .001 for non-inferiority and P = .003 for superiority)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}